Qiagen bids $355 million for Australian diagnostics firm

Qiagen NV, the Netherlands-based diagnostic group, has made a bid equivalent to $355 million to acquire Cellestis Ltd of Australia and its ‘pre-molecular’ technology for detecting diseases early.